1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC).
Saved in:
| Title: | 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC). |
|---|---|
| Authors: | Martin Romano, P.1 (AUTHOR), Roubaud, G.2 (AUTHOR), Lavaud, P.3 (AUTHOR), Cabart, M.4 (AUTHOR), Pages, A.5 (AUTHOR), Vasseur, D.6 (AUTHOR), Colomba, E.7 (AUTHOR), Cousin, S.8 (AUTHOR), Toulmonde, M.9 (AUTHOR), Grellety, T.10 (AUTHOR), Castel Ajgal, Z.11 (AUTHOR), Chabanon, R.12 (AUTHOR), Parpaleix, A.13 (AUTHOR), Buzzatti, G.14 (AUTHOR), Fizazi, K.15 (AUTHOR), Gomez-Roca, C.A.16 (AUTHOR), Italiano, A.10 (AUTHOR), Loriot, Y.15 (AUTHOR), Postel-Vinay, S.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1334-S1334. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.1820 |
